HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Secretory Leukocyte Peptidase Inhibitor

Subscribe to New Research on Secretory Leukocyte Peptidase Inhibitor

A proteinase inhibitor found in various BODILY SECRETIONS that coat mucosal surfaces such as SEMINAL PLASMA; CERVICAL MUCUS; and bronchial secretions. It plays a role in protecting epithelial tissues from LEUKOCYTE-derived serine proteases such as NEUTROPHIL ELASTASE.

Also Known As:

Antileukoprotease; Bronchial Mucus Elastase Inhibitor; Elastase Inhibitor, Mucus; Leukocyte Peptidase Inhibitor, Secretory; Mucus Protease Inhibitor; Mucus Proteinase Inhibitor; Secretory Leukocyte-Protease Inhibitor; Secretory Leukoprotease Inhibitor; Seminal Proteinase Inhibitor; Mucus Elastase Inhibitor; Protease Inhibitor, Mucus; Proteinase Inhibitor, Mucus; Secretory Leukocyte Protease Inhibitor

Networked: 217 relevant articles (4 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Secretory Proteinase Inhibitory Proteins: 23
    - Secretory Leukocyte Peptidase Inhibitor: 217
- Peptides: 22950
  - Secretory Proteinase Inhibitory Proteins: 23
    - Secretory Leukocyte Peptidase Inhibitor: 217

Experts

1.	Jeong, Moon-Jin: 5 articles (02/2012 - 08/2004)
2.	Wahl, Sharon M: 5 articles (01/2012 - 08/2004)
3.	Curiel, David T: 5 articles (02/2005 - 03/2003)
4.	Görögh, Tibor: 4 articles (02/2015 - 07/2011)
5.	Hoffmann, Markus: 4 articles (02/2015 - 07/2011)
6.	Röcken, Christoph: 4 articles (02/2015 - 07/2011)
7.	Sallenave, Jean-Michel: 4 articles (01/2015 - 04/2004)
8.	Nukiwa, Toshihiro: 4 articles (04/2014 - 03/2003)
9.	Kikuchi, Toshiaki: 4 articles (04/2014 - 03/2003)
10.	McElvaney, Noel G: 4 articles (01/2013 - 11/2007)

Related Diseases

1.	Emphysema 06/01/2002 - "Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema." 10/01/1986 - "These results do not support a protective activity of antileukoprotease against emphysema, but neither do they provide evidence against it." 12/01/1994 - "Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema." 03/01/1992 - "Alpha 1-proteinase inhibitor and mucus proteinase inhibitor in human lung emphysema." 05/01/1989 - "Twenty-seven surgically removed lungs and lobes were studied to assess the relation between the abundance of bronchiolar epithelial cells containing antileukoprotease (ALP) (ALP-pos/mm) and the degree of small airways disease (SADscore) and emphysema (destructive index = DI, and number of normal alveolar attachments on membranous bronchioles = normal AA/min). "
2.	Drug Toxicity (Drug Safety) 11/01/1999 - "Studies in both patient groups using plasma-derived or transgenic alpha(1)-AT, recombinant secretory leukoprotease inhibitor or synthetic elastase inhibitors show promising results concerning drug safety and efficacy."
3.	Spinal Cord Injuries (Spinal Cord Injury) 01/01/2010 - "Furthermore, wild-type mice treated for the first week after spinal cord contusion injury with recombinant secretory leukocyte protease inhibitor exhibit sustained improvement in locomotor control and reduced secondary tissue damage. " 01/01/2010 - "Administration of recombinant secretory leukocyte protease inhibitor might therefore be useful for the treatment of acute spinal cord injury." 01/01/2010 - "We show, using transgenic mice over-expressing secretory leukocyte protease inhibitor, that this molecule has an early protective effect after spinal cord contusion injury. " 01/01/2010 - "After spinal cord contusion injury in mice, secretory leukocyte protease inhibitor is expressed primarily by astrocytes and neutrophils but not macrophages. " 01/01/2010 - "We now report a beneficial role for secretory leukocyte protease inhibitor after spinal cord injury. "
4.	Colitis 01/01/2015 - "In order to identify the best strategy to treat IBD using recLAB, we compared the efficacy of different recombinant strains of Lactococcus lactis (the model LAB) secreting two types of anti-inflammatory molecules: cytokines (IL-10 and TGF-β1) and serine protease inhibitors (Elafin and Secretory Leukocyte Protease Inhibitor: SLPI), using a dextran sulfate sodium (DSS)-induced mouse model of colitis. "
5.	Infection 05/01/2000 - "In the present study, we demonstrate that recombinant human secretory leukocyte protease inhibitor (rhSLPI) inhibits infection of lymphocyte- and monocyte-derived tumor cell lines and peripheral blood lymphocytes with laboratory-adapted isolates and with the primary isolate, NDK, of free human immunodeficiency virus type 1 (HIV-1). " 11/15/2004 - "The distribution of secretory leukocyte protease inhibitor (SLPI) at entry portals indicates its involvement in defending the host from pathogens, consistent with the ability of SLPI to inhibit human immunodeficiency virus (HIV)-1 infection by an unknown mechanism. " 08/01/2002 - "The ability of the salivary protein, secretory leukocyte protease inhibitor (SLPI), to inhibit human immunodeficiency virus-1 (HIV-1) infection in vitro has been reported previously and has led to the suggestion that SLPI may be partially responsible for the low oral transmission rate of HIV-1. " 08/01/2002 - "Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein." 11/01/2000 - "Levels of secretory leukocyte protease inhibitor in vaginal fluid are decreased in women with lower genital tract infection. "

Related Drugs and Biologics

1.	Elafin
2.	Pancreatic Elastase (Elastase)
3.	Cytokines
4.	Dextran Sulfate
5.	Serine Proteinase Inhibitors (Serine Protease Inhibitors)
6.	STF 62247
7.	acetovanillone (apocynin)
8.	Lactoferrin
9.	Leukocyte Elastase (Neutrophil Elastase)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart)